弥漫性大B细胞淋巴瘤的定量影像组学特征:分割方法是否重要?
该研究匹配了50例2年内进展或复发的DLBCL患者与50例无进展患者的基线18F-FDG PET/CT,采用6种半自动分割方法提取影像组学特征。结果显示不同分割方法提取的特征值及所选特征存在差异,但影像组学特征的判别能力无实质性差异。
要点
- 6种半自动分割方法提取的影像组学特征值及所选特征存在差异。
- 不同分割方法间影像组学特征的判别能力(ROC曲线下面积)无实质性差异。
- 与SUV4.0分割相比,50%SUVpeak分割中ICC≥0.75的特征比例最低。
核心结论
- 尽管不同分割方法导出的实际影像组学特征值和所选特征存在差异,但影像组学特征的判别能力在各分割方法间无实质性差异。
研究设计与样本
- 匹配了50例诊断后2年内进展或复发的DLBCL患者与50例无进展患者的基线18F-FDG PET/CT扫描,匹配条件为摄取时间和重建方法。
- 使用6种半自动分割方法(SUV4.0、SUV2.5、41%SUVmax、50%SUVpeak、多数投票法分割≥2种方法检测的体素、多数投票法分割≥3种方法检测的体素)进行分析。
- 在患者水平提取490个影像组学特征,最大病灶提取486个特征;以SUV4.0为参照计算组内相关系数(ICC)一致性。
- 通过删除与已建立的预测因子MTV或SUVpeak具有高Pearson相关性(≥0.7)的特征来缩减特征空间。
- 采用分层重复交叉验证(5折,2000次重复)评估模型性能,使用逻辑回归后退特征选择,计算所有分割方法的平均ROC曲线下面积。
主要发现
- 与SUV4.0分割相比,ICC≥0.75的特征百分比在患者水平和最大病灶水平均以50%SUVpeak分割最低,分别为77.3%和66.7%。
- 所有分割方法中,患者水平至少有435个特征、最大病灶至少有409个特征与MTV的相关系数小于0.7。
- 与SUVpeak强相关的特征较多:患者水平至少有190个特征、最大病灶至少有134个特征与SUVpeak不相关。
- ROC曲线下面积在患者水平为0.69±0.11至0.84±0.09,在病灶水平为0.69±0.11至0.73±0.10。
关键数值与推荐
- ICC≥0.75的特征百分比在50%SUVpeak分割中最低:患者水平77.3%,最大病灶水平66.7%。
- 与MTV相关系数<0.7的特征数:患者水平至少435个,最大病灶至少409个(所有分割方法)。
- 与SUVpeak不相关的特征数:患者水平至少190个,最大病灶至少134个。
- ROC曲线下面积范围:患者水平0.69±0.11至0.84±0.09,病灶水平0.69±0.11至0.73±0.10。
临床怎么用
- 在DLBCL的18F-FDG PET/CT影像组学分析中,分割方法的选择对特征值和所选特征有影响,但对判别能力无实质性影响。
- 临床研究中可参考本研究的6种半自动分割方法及其一致性数据,但需注意50%SUVpeak分割与SUV4.0的一致性相对最低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radiomics features may predict outcome in diffuse large B-cell lymphoma (DLBCL). Currently, multiple segmentation methods are used to calculate metabolic tumor volume (MTV). We assessed the influence of segmentation method on the discriminative power of radiomics features in DLBCL at the patient level and for the largest lesion. Methods: Fifty baseline 18F-FDG PET/CT scans of DLBCL patients with progression or relapse within 2 years after diagnosis were matched on uptake time and reconstruction method with 50 baseline PET/CT scans of DLBCL patients without progression. Scans were analyzed using 6 semiautomatic segmentation methods (SUV threshold of 4.0 [SUV4.0], SUV threshold of 2.5, 41% of SUVmax, 50% of SUVpeak, a majority vote segmenting voxels detected by ≥2 methods, and a majority vote segmenting voxels detected by ≥3 methods). On the basis of these segmentations, 490 radiomics features were extracted at the patient level, and 486 features were extracted for the largest lesion. To quantify the agreement between features extracted from different segmentation methods, the intraclass correlation (ICC) agreement was calculated for each method compared with SUV4.0. The feature space was reduced by deleting features that had high Pearson correlations (≥0.7) with the previously established predictors MTV or SUVpeak Model performance was assessed using stratified repeated cross validation with 5 folds and 2,000 repeats, yielding the mean receiver-operating-characteristics curve integral for all segmentation methods using logistic regression with backward feature selection. Results: The percentage of features yielding an ICC of at least 0.75, compared with the SUV4.0 segmentation, was lowest for 50% of SUVpeak both at the patient level and for the largest lesion, with 77.3% and 66.7% of the features yielding an ICC of at least 0.75, respectively. Features did not correlate strongly with MTV, with at least 435 features at the patient level and 409 features for the largest lesion for all segmentation methods having a correlation coefficient of less than 0.7. Features correlated strongly with SUVpeak (at least 190 at patient level and 134 for the largest lesion were uncorrelated to SUVpeak, respectively). Receiver-operating-characteristics curve integrals ranged between 0.69 ± 0.11 and 0.84 ± 0.09 at the patient level and between 0.69 ± 0.11 and 0.73 ± 0.10 at the lesion level. Conclusion: Even though there are differences in the actual radiomics feature values derived and selected features among segmentation methods, there is no substantial difference in the discriminative power of radiomics features among segmentation methods.
引用
- Eertink JJ, Pfaehler EAG, Wiegers SE, et al. Quantitative Radiomics Features in Diffuse Large B-Cell Lymphoma: Does Segmentation Method Matter? J Nucl Med. 2021. PMID: 34272315. doi:10.2967/jnumed.121.262117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。